Karuna Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Nov 26, 2019--
Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Andrew Miller, Ph.D., founder and chief operating officer at Karuna, will present and host investor meetings at the Piper Jaffray 31st Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY. The Company is scheduled to present on Thursday, December 5, 2019, at 12:30 p.m. ET.
A live webcast of the presentation will also be available on the investor relations page of the Karuna corporate website at investors.karunatx.com. After the live webcast, the event will remain archived on the Karuna website for 90 days.
Karuna is a clinical-stage biopharmaceutical company committed to developing and delivering first-in-class therapies with the potential to transform the lives of people with CNS disorders – which remain among the most disabling and potentially fatal disorders worldwide. Galvanized by the understanding that today’s neuropsychiatric and pain management patients deserve better, Karuna’s mission is to harness the untapped potential of the brain’s complex biology in pursuit of novel therapeutic pathways that will advance the standard of care. For more information, please visit karunatx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191126005257/en/
CONTACT: Investor Contact:
Westwicke, an ICR Company
+1 339 970-2843
firstname.lastname@example.org Media Contact:
+1 202 587-2580
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK MASSACHUSETTS
INDUSTRY KEYWORD: MENTAL HEALTH HEALTH RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY
SOURCE: Karuna Therapeutics, Inc.
Copyright Business Wire 2019.
PUB: 11/26/2019 07:00 AM/DISC: 11/26/2019 07:01 AM